Unplanned long-term analysis of a phase 2 trial in 157 men with oligometastatic castrate-resistant prostate cancer: adding SBRT to abiraterone acetate and ADT was linked to longer overall survival (median NR vs 50 months; HR 0·55, 95% CI 0·33–0·92).
RCTn = 157
Francolini et al. SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial